Direxion Daily S&P Biotech Bull 3X Shares (LABU) Shows +36% Gain Over 30 Days and +85% for the Quarter

Key Takeaways

• LABU rose about +36% over the past 30 days, driven by a strong rally in the S&P Biotechnology Select Industry Index and the fund’s 3x daily leverage.
• The ETF also posted solid quarterly results, advancing roughly +85% as biotechnology regained leadership within U.S. equities.
• As a leveraged product, LABU targets 300% of the daily return of its benchmark, so moves are amplified and performance resets each day.
• Healthcare accounts for nearly all of the fund’s equity exposure, with biotechnology holdings such as Apellis Pharmaceuticals, Revolution Medicines, Travere Therapeutics, and Arrowhead Pharmaceuticals among the largest positions.
• Investors need to balance the fund’s concentration, volatility, and daily reset mechanics against the recent sector momentum.

LABU Overview and Portfolio Exposure

LABU is a leveraged, non-diversified ETF that aims for daily results, before fees and expenses, equal to 300% of the S&P Biotechnology Select Industry Index. Direxion manages the fund, which typically gains exposure through index swaps, index securities, and other instruments rather than holding every underlying stock directly.

The benchmark focuses on the biotechnology sub-industry inside healthcare. As a result, the fund’s equity exposure sits almost entirely in biotechnology, with healthcare making up virtually the full stock allocation. The portfolio contains roughly 170 positions across index holdings, swaps, and cash, and top names have included Apellis Pharmaceuticals, Revolution Medicines, Travere Therapeutics, and Arrowhead Pharmaceuticals. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

The net expense ratio stands at 0.96%, with assets under management in the several-hundred-million-dollar range. The 3x leverage and narrow sector focus create significantly higher volatility than a standard healthcare ETF, which helps explain the outsized recent returns relative to the broader market.

Price Performance: 30 Days Versus the Quarter

Over the trailing 30 days, LABU climbed approximately +36%, moving from a close near $246 to roughly $335. The advance was not smooth; the fund saw notable intraday and day-to-day swings, which is typical for a leveraged vehicle tied to a high-beta sector.

The three-month view is even stronger. From a close near $181 one quarter earlier, LABU has risen about +85%. This shows the recent 30-day move forms part of a broader, multi-month uptrend in biotechnology rather than a one-off spike.

The character of the move has been trend-driven yet volatile. Sharp rallies have been interrupted by pullbacks, a pattern often seen when daily 3x leverage compounds on an already volatile index. The overall direction has stayed upward across both the monthly and quarterly periods. From what I see, the longer-term trend remains intact.

Drivers of the 30-Day Advance

The recent surge stems from several factors centered on biotechnology. Because LABU delivers three times the daily return of its benchmark, any move in the underlying index is roughly tripled each day, which remains the primary mechanical driver of the fund’s gains.

Many of the underlying holdings are clinical-stage or small- to mid-cap biotechnology companies that react sharply to clinical data, regulatory approvals, and M&A activity. Renewed investor interest in innovation-driven healthcare assets has lifted these names, and the fund’s broad exposure has converted that strength into meaningful appreciation.

On the macro side, biotechnology is viewed as a rate-sensitive sector where interest-rate expectations and risk sentiment influence valuations. An improving appetite for growth equities has supported the group. The combination of favorable sector sentiment, active dealmaking, and leverage helped fuel the 30-day move, even with elevated intraday volatility.

Drivers of the Quarterly Performance

Over the trailing quarter, LABU’s roughly +85% advance reflects a sustained rotation back into biotechnology and growth-oriented healthcare. While the 30-day move captures recent momentum, the three-month trend shows a broader shift in sector leadership after a period of relative underperformance.

Several forces have supported the longer move. Continued consolidation in biotechnology has benefited both acquirers and targets across the holdings. A more constructive interest-rate environment has eased pressure on the discounted valuations of development-stage companies that make up a meaningful portion of the index. Steady pipeline progress in areas such as oncology, rare diseases, and metabolic disorders has also reinforced fundamentals.

Institutional flows into leveraged and thematic funds during strong trends have added to the momentum. The net result over three months has been a powerful upward move that exceeds what an unleveraged biotech ETF would typically deliver.

Outlook: Factors to Monitor

Several elements are likely to influence LABU going forward. Interest-rate direction remains key given the sector’s sensitivity to monetary policy and long-duration valuations. Inflation data and central-bank commentary will therefore matter for biotechnology multiples.

Sector-specific catalysts also deserve attention. Clinical trial results and regulatory decisions on the fund’s largest holdings can generate sharp moves that, under 3x leverage, translate into pronounced ETF volatility. The pace of M&A activity will be another important variable, as consolidation has repeatedly supported biotech strength.

Investors should also keep the structural risks of leveraged products in mind. Because LABU resets daily, returns over periods longer than one day can differ substantially from three times the index’s cumulative return, especially in choppy markets. Volatility decay, concentration risk, and the potential for rapid drawdowns are inherent considerations.

Using Tickeron’s AI Tools for Further Research

I regularly turn to Tickeron’s AI Screener when analyzing leveraged sector ETFs like LABU. The platform lets me scan thousands of securities with technical indicators, fundamentals, volatility metrics, price patterns, and AI-generated signals in one place. It helps surface comparable opportunities and confirm whether a move in one name or sector stands out relative to peers. For anyone tracking high-momentum areas such as biotechnology, it offers a structured way to organize research without replacing individual judgment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Jimmy Landsman|Expert

My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume